Publications by authors named "Jason D Katz"

Claim this Profile
C
Correction to "Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor".
Dong-Ming Shen, Kate F Byth, Damien Bertheloot, Simona Braams, Sarah Bradley, Jason D Katz

J Med Chem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor.
Dong-Ming Shen, Kate F Byth, Damien Bertheloot, Simona Braams, Sarah Bradley, Jason D Katz

J Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cGAS-STING pathway as a therapeutic target in inflammatory diseases.
Alexiane Decout, Jason D Katz, Shankar Venkatraman, Andrea Ablasser

Nat Rev Immunol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a new series of PI3K-δ inhibitors from Virtual Screening.
Xavier Fradera, Qiaolin Deng, Abdelganhi Achab, Yudith Garcia, Solomon D Kattar, Jason D Katz

Bioorg Med Chem Lett· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Divergent and Regioselective Synthesis of Pyrazolo[1,5-]pyridines and Imidazo[1,5-]pyridines.
Katrina M Mennie, Michael H Reutershan, Catherine White, Bruce Adams, Bridget Becker, Jason D Katz

Org Lett· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators.
Joey L Methot, Hua Zhou, Meredeth A McGowan, Neville John Anthony, Matthew Christopher, Jason D Katz

J Med Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Versatile Oxindoles as Selective PI3Kδ Inhibitors.
Joey L Methot, Abdelghani Achab, Matthew Christopher, Hua Zhou, Meredeth A McGowan, Jason D Katz

ACS Med Chem Lett· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow" [Bioorg. Med. Chem. Lett. 29 (2019) 2575-2580].
Xavier Fradera, Joey L Methot, Abdelghani Achab, Matthew Christopher, Michael D Altman, Jason D Katz

Bioorg Med Chem Lett· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors.
Hua Zhou, Meredeth A McGowan, Kathryn Lipford, Matthew Christopher, Xavier Fradera, Jason D Katz

Bioorg Med Chem Lett· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow.
Xavier Fradera, Joey L Methot, Abdelghani Achab, Matthew Christopher, Michael D Altman, Jason D Katz

Bioorg Med Chem Lett· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability.
Joey L Methot, Hua Zhou, Sam D Kattar, Meredeth A McGowan, Kevin Wilson, Jason D Katz

J Med Chem· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.
Jason D Katz, Andrew Haidle, Kaleen K Childers, Anna A Zabierek, James P Jewell

Bioorg Med Chem Lett· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation.
Andrew M Haidle, Kaleen K Childers, Anna A Zabierek, Jason D Katz, James P Jewell

Bioorg Med Chem Lett· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.
Vladimir Simov, Sujal V Deshmukh, Christopher J Dinsmore, Fiona Elwood, Rafael B Fernandez, Jason D Katz

Bioorg Med Chem Lett· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.
Jason D Katz, James P Jewell, David J Guerin, Jongwon Lim, Christopher J Dinsmore

J Med Chem· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Bo-Sheng Pan, Grace K Y Chan, Melissa Chenard, An Chi, Lenora J Davis, Jason D Katz

Cancer Res· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation of a stable trifluoroborate salt for the synthesis of 1-aryl-2,2-difluoro-enolethers and/or 2,2-difluoro-1-aryl-ketones via palladium-mediated cross-coupling.
Jason D Katz, Blair T Lapointe, Christopher J Dinsmore

J Org Chem· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asymmetric total synthesis of spongistatins 1 and 2.
Michael T Crimmins, Jason D Katz, David G Washburn, Shawn P Allwein, Laura F McAtee

J Am Chem Soc· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis